07 August, 2017
Gabelli analyst K. Kedra now anticipates that the company will post earnings of $4.00 per share for the year, down from their previous estimate of $4.20. Equities analysts expect that Endo International PLC will post $3.54 EPS for the current year.
Zacks trimmed stocks of Endo International (NASDAQ:ENDP) from a hold recommendation to a sell recommendation in a study report announced on early Tue, Jul 11th. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The business had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. In contrast to the year ago quarter EPS was at 1.24. Company's sales went up 7.7% compared with the same period in the prior year. Moreover, Bessemer Group Incorporated has 0% invested in Endo International plc - Ordinary Shares (NASDAQ:ENDP) for 1,335 shares. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of USA and worldwide trademark and copyright laws.
Large investors have recently bought and sold shares of the stock. Susquehanna upgraded the shares of ENDP in report on Thursday, November 10 to "Positive" rating. Canaccord Genuity fixed a $14.00 target price on Endo International and issued the shares a hold recommendation in a note on Tue, Mar 14th. BMO Capital Markets restated a hold rating and set a $15.00 price objective on shares of Endo International PLC in a research note on Monday, May 1st. Mizuho reissued a "buy" rating and issued a $18.00 price target (up from $17.00) on shares of Endo International PLC in a report on Thursday, April 13th. On June 9 the stock rating was downgraded to "Hold" from "Buy" in a report issued by Stifel Nicolaus. The company has an average rating of "Hold" and a consensus target price of $17.33.
Analysts on average have given a price target of $14.71 to Endo International plc (ENDP) stock. 10,515,777 shares of the stock were exchanged. The stock closing price is now trading downward to its 50 day moving average with change of -20.04%, tumbled to its 20 day moving average with figure of -18.27% and behind its 200 day moving average with value -29.44%.
Among 21 analysts covering Endo International plc (NASDAQ:ENDP), 8 have Buy rating, 0 Sell and 13 Hold. The 9 months bearish chart indicates high risk for the $2.21B company. Maestri Luca sold $2.95M worth of stock or 20,307 shares.
Endo International plc - Ordinary Shares has 52 week low of $9.36 and a 52 week high of $24.93 and has a market capitalization of $0. Macquarie Group Ltd. now owns 6,500 shares of the company's stock valued at $107,000 after buying an additional 3,700 shares during the last quarter. Point View Wealth Management Inc. raised its stake in Endo International PLC by 12.3% in the first quarter. Capstone Asset Management has an ownership of 32,035 company stock worth at $358,000 after scooping up an extra 960 shares through out the previous quarter, Lastly, Point View Wealth Management increased its position in Endo International by 12.3% in the Q1. Jensen Investment Management Inc. increased its position in shares of Endo International PLC by 5.8% in the first quarter. Endo International plc - Ordinary Shares (NASDAQ:ENDP) has declined 19.57% since August 4, 2016 and is downtrending. Finally, Rhumbline Advisers increased its stake in Endo International PLC by 5.4% in the second quarter. Gamco Investors INC. ET AL now owns 62,700 shares of the company's stock valued at $700,000 after buying an additional 3,300 shares during the period.
A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ's health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs.
